JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

Abstract CDK4/6 inhibitors in combination with endocrine therapy are now used as front-line treatment for patients with estrogen-receptor positive (ER+) breast cancer. While this combination improves overall survival, the mechanisms of disease progression remain poorly understood. Here, we performed...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah Alexandrou, Christine S. Lee, Kristine J. Fernandez, Celine E. Wiharja, Leila Eshraghi, John Reeves, Daniel A. Reed, Neil Portman, Zoe Phan, Heloisa H. Milioli, Iva Nikolic, Antonia L. Cadell, David R. Croucher, Kaylene J. Simpson, Elgene Lim, Theresa E. Hickey, Ewan K. A. Millar, Carla L. Alves, Henrik J. Ditzel, C. Elizabeth Caldon
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
CDK4/6 inhibition
Palbociclib
ER+ breast cancer
JNK signalling
Endocrine therapy
Online Access:https://doi.org/10.1186/s13046-025-03466-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-025-03466-9

Similar Items